Respiratory Delivery of Highly Conserved Antiviral siRNAs Suppress SARS-CoV-2 Infection
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262311675 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Yuan Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia. Hauptthemen laut MEDLINE: SARS-CoV-2, RNA, Small Interfering, COVID-19, Antiviral Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Government, the Australian Government’s Medical Research Future Fund, Australian Government Research Training Program (RTP) scholarship.
Abstract (Originalsprache)
COVID-19 has resulted in over 777 million confirmed cases and more than 7 million deaths globally. While vaccination offers protection for individuals with a functional immune system, immunocompromised populations will not generate sufficient responses, highlighting the critical need for new antiviral treatments. Here we evaluated four highly conserved anti-COVID siRNAs targeting the ORF1a-Nsp1, Membrane, and Nucleocapsid regions by identifying their antiviral efficacy in vitro and investigated the direct delivery of naked siRNAs to the respiratory tract of mice via intranasal instillation to provide proof-of-concept evidence of their in vivo antiviral activity. Dose-response analysis of siRNAs revealed a range of IC50 0.02 nM to 0.9 nM. Intranasal administration of naked anti-COVID siRNA-18 in a K18-hACE2 transgenic SARS-CoV-2 mouse model was capable of reducing viral mRNA levels and disease severity. While anti-COVID siRNA-30 induced modest interferon-stimulated gene expression in vitro and immune cell infiltration in vivo, these effects were markedly reduced by 2′-O-methyl-AS456 chemical modification, which preserved antiviral efficacy against SARS-CoV-2 while minimizing off-target immune activation. These results demonstrate the feasibility of direct respiratory siRNA administration for in vivo viral suppression and highlight the benefit of using conserved target sequences and chemical modification to enhance therapeutic safety and efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
- Centre for Inflammation, School of Life Sciences, Faculty of Science, Centenary Institute and University of Technology Sydney, Sydney, NSW 2050, Australia.
- RNA Institute, University of New South Wales, Sydney, NSW 2052, Australia.
ORCID-Profile: Yuan Zhang, Matt D Johansen, Pall Thordarson, Philip M Hansbro, Anthony D Kelleher, Chantelle L Ahlenstiel
Förderung
- Australian Government
- the Australian Government’s Medical Research Future Fund
- Australian Government Research Training Program (RTP) scholarship
- the UTS Chancellor’s Research Fellowship
Zitieren
APA
Zhang, Y., Johansen, M. D., Ledger, S., Turville, S., Thordarson, P., Hansbro, P. M., Kelleher, A. D., & Ahlenstiel, C. L. (2025). Respiratory Delivery of Highly Conserved Antiviral siRNAs Suppress SARS-CoV-2 Infection. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262311675
Vancouver
Zhang Y, Johansen MD, Ledger S, Turville S, Thordarson P, Hansbro PM, et al. Respiratory Delivery of Highly Conserved Antiviral siRNAs Suppress SARS-CoV-2 Infection. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262311675
BibTeX
@article{Zhang2025,
author = {Zhang, Yuan and Johansen, Matt D and Ledger, Scott and Turville, Stuart and Thordarson, Pall and Hansbro, Philip M and Kelleher, Anthony D and Ahlenstiel, Chantelle L},
title = {Respiratory Delivery of Highly Conserved Antiviral siRNAs Suppress SARS-CoV-2 Infection},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262311675}
}
EUVIMED